In this webinar we will describe how the Specifica Generation 3 platform, a semi-synthetic naïve antibody library that relies on whole natural CDRs for diversity, fared in this global competition: yielding antibodies more similar in their
properties to immune, as opposed to naïve, sources. Analysis of 96 picked clones resulted in 31 unique antibodies (falling into 12 sequence clusters), 19 of which had subnanomolar affinities, and three of which had affinities below 100
pM. Eight of ten tested antibodies had IC50’s <10ng/ml, with four having live virus IC50’s <2ng/ml, including one with an IC50 of 1.3 ng/ml. The antibodies showed excellent developability properties, with 95% having one or
zero sequence liabilities, and none showing any polyreactive behavior. Expanding the analysis by Next Generation Sequencing using software developed by Specifica and to be co-commercialized by OpenEye and Specific increased the number of different
specific antibody clusters to over 600.
Key Learning Objectives:
- How do the world’s different antibody discovery platforms perform when tested against the same target?
- Immune libraries generally provide better antibodies in terms of affinity and viral neutralization than naïve libraries
- The Specifica Generation 3 platform performs more like an immune library than a naïve one
- NGS increases the number of unique antibody clusters identified by approximately fifty-fold, compared to random picking
Andrew Bradbury, MD PhD
Chief Scientific Officer
Andrew Bradbury is Chief Scientific Officer of Specifica. He trained in medicine at the universities of Oxford and London and received his PhD from the university of Cambridge at the MRC Laboratory of Molecular Biology under the guidance of Nobel
Laureate, Cesar Milstein. He has worked in the fields of phage and yeast display, library generation, antibody engineering and Next Generation Sequencing for up to thirty years. He was a Group Leader at Los Alamos National Laboratory before
Frank Erasmus, PhD
M. Frank Erasmus is head of bioinformatics at Specifica, Inc. He has over 11 years of experience incorporating both experimental and computational approaches to antibody-based drug discovery. His work has directly contributed to the development
of novel therapeutic monoclonal antibodies with implications in leukemia and antibody libraries built exclusively for the biotech community. He is currently focusing on the development of tools for the biopharma industry to extract patterns
from next generation sequencing data derived from recombinant display technologies.
Cost: No Cost!